Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.36 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.35 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.35 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.35 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.35 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.35 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.35 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.34 |
| ▸ | NTRK1 known ✓ | P04629 | 2/20 | 0.34 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.54 |
| ▸ | CLK1 | P49759 | 5/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21893812 | 0.98 | GSK3B (0.56) | GSK3BCLK1DYRK1ACCNT1CCNA2 | |
| SCHEMBL23165972 | 0.82 | GSK3B (0.43) | GSK3BCLK1DYRK1ACCNT1CCNA2 | |
| SCHEMBL15154998 | 0.76 | GSK3B (0.56) | GSK3BCCNT1CCNA2CDK2CDK9 | |
| SCHEMBL1880862 | 0.76 | BRD4 (0.47) | GSK3BCLK1DYRK1ACDK2GSK3A | |
| SCHEMBL14041214 | 0.76 | MET (0.43) | GSK3BGSK3AKITCYP3A4 | |
| SCHEMBL29605509 | 0.76 | AXL (0.47) | GSK3BCLK1DYRK1ACCNT1CCNA2 | |
| SCHEMBL1564507 | 0.76 | GSK3B (0.56) | GSK3BCLK1DYRK1ACDK2CDK9 | |
| SCHEMBL14678434 | 0.76 | AXL (0.47) | GSK3BCLK1DYRK1ACCNT1CCNA2 | |
| SCHEMBL14685266 | 0.76 | CLK1 (0.39) | GSK3BCLK1DYRK1ACDK2GSK3A | |
| SCHEMBL15155041 | 0.76 | GSK3B (0.56) | GSK3BCCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004785-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-112823036-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| CN-116528862-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-4182028-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220227760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-07-21 | — | — | US | disclosed |
| EP-3976584-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-112823036-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3817820-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020243519-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KIT 1403/4885PIK3CA 678/4885PIK3CD 830/4885 |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KIT 1403/4885PIK3CA 678/4885PIK3CD 830/4885 |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | KIT 693/4885PIK3CA 910/4885PIK3CD 1069/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KIT 1403/4885PIK3CA 678/4885PIK3CD 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.